The present invention relates to a system for manufacturing a nanoparticle composition which is for targeted therapy and comprises a radioactive isotope, the system comprising a reaction device, wherein the reaction device comprises: a stirring module configured to stir a reactant solution prepared in a reaction vessel; and a heating module configured to heat the stirred reactant solution to obtain a solution including an intermediate product, and the prepared reactant solution comprises at least one of a nanoparticle composition precursor including a hydrophobic or hydrophilic organic compound-metal complex, an inorganic compound and an organic solvent, a first mixture including a radioisotope, and a second mixture including a hydrophilic organic polymer.
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
A61K 47/30 - Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
B01J 19/12 - Processes employing the direct application of electric or wave energy, or particle radiationApparatus therefor employing electromagnetic waves
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
2.
METHOD FOR PRODUCING IRON OXIDE BASED NANOPARTICLES, AND IRON OXIDE BASED NANOPARTICLES FORMED THEREFROM
A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
The present invention provides iron oxide magnetic particles containing iron oxide and MXn, wherein M as a transition metal containing electrons in a 5d orbital on the periodic table includes one or more selected from the group consisting of Hf, Ta, W, Re, Os, Ir, Pt, Au, and Hg, X includes one or more selected from the group consisting of F, Cl, Br, and I, and n is an integer of 1 to 6.
A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
The present invention provides iron oxide magnetic particles containing iron oxide and MXn, wherein M as a transition metal containing electrons in a 6p orbital on the periodic table includes one or more selected from the group consisting of Tl, Pb, Bi, and Po, X includes one or more selected from the group consisting of F, Cl, Br, and I, and n is an integer of 1 to 6.
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
5.
COMPOSITION COMPRISING IRON OXIDE MAGNETIC PARTICLES FOR A TREATMENT OF LIVER CANCER
Disclosed is a composition comprising iron oxide magnetic particles. The composition is delivered to a liver in a hepatocyte-specific manner to minimize damage to other organs, and is safely excreted from a body within a few weeks. Further, the particles have excellent hepatocyte targeting ability, and thus are used as a liver cancer treatment agent and a hepatocyte targeting carrier.
METHOD FOR PREPARING COMPOSITION FOR TREATING LIVER CANCER, COMPRISING IRON OXIDE MAGNETIC PARTICLES, AND COMPOSITION FOR TREATING LIVER CANCER, COMPRISING IRON OXIDE MAGNETIC PARTICLES
The present invention relates to a method for preparing a composition comprising iron oxide magnetic particles, and a composition comprising iron oxide magnetic particles, wherein the composition prepared by the preparation method is delivered specifically to liver cells so that damage to other organs can be minimized, and is excreted from the body after several weeks, and thus is safe. In addition, the present invention has excellent liver-cell-targeting property, and thus can be used in liver cancer treatment and as a liver cell-targeted carrier.
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
The present invention relates to a composition comprising iron oxide magnetic particles. The composition can be delivered specifically to hepatocytes to minimize damage to other organs, and is safe as the composition is excreted from the body within a few weeks. In addition, the composition has excellent hepatocellular-targeting properties, and thus can be used for liver cancer treatment and as a hepatocellular target delivery system.
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
nn, wherein M includes at least one selected from the group consisting of Hf, Ta, W, Re, Os, Ir, Pt, Au, and Hg, X includes at least one selected from the group consisting of F, Cl, Br and I, and n is an integer of 1 to 6.
A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
B82Y 15/00 - Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
B82Y 40/00 - Manufacture or treatment of nanostructures
nn, wherein M is a transition metal with an electron occupying the 6p orbital on the periodic table and includes at least one selected from the group consisting of Tl, Pb, Bi, and Po, X includes at least one selected from the group consisting of F, Cl, Br, and I, and n is an integer of 1 to 6.
A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
B82Y 15/00 - Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
B82Y 40/00 - Manufacture or treatment of nanostructures
The present invention provides iron oxide magnetic particles comprising iron oxide and MXn, wherein M comprises at least one selected from the group consisting of Cu, Sn, Pb, Mn, Ir, Pt, Rh, Re, Ag, Au, Pd and Os, X comprises at least one selected from the group consisting of F, Cl, Br and I, and n is an integer of 1 to 6.
H01F 1/00 - Magnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties
H01F 1/06 - Magnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties of inorganic materials characterised by their coercivity of hard-magnetic materials metals or alloys in the form of particles, e.g. powder
n, wherein M includes one or more selected from the group consisting of Cu, Sn, Pb, Mn, Ir, Pt, Rh, Re, Ag, Au, Pd, and Os, X includes one or more selected from the group consisting of F, Cl, Br, and I, and n is an integer of 1 to 6.
H01F 1/00 - Magnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties
H01F 1/34 - Magnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties of inorganic materials characterised by their coercivity of soft-magnetic materials non-metallic substances, e.g. ferrites
H01F 1/06 - Magnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties of inorganic materials characterised by their coercivity of hard-magnetic materials metals or alloys in the form of particles, e.g. powder
H01F 1/09 - Magnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties of inorganic materials characterised by their coercivity of hard-magnetic materials mixtures of metallic and non-metallic particlesMagnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties of inorganic materials characterised by their coercivity of hard-magnetic materials metallic particles having oxide skin
nn, wherein M comprises at least one selected from the group consisting of Cu, Sn, Pb, Mn, Ir, Pt, Rh, Re, Ag, Au, Pd and Os, X comprises at least one selected from the group consisting of F, Cl, Br and I, and n is an integer of 1 to 6.
H01F 1/00 - Magnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties
H01F 1/06 - Magnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties of inorganic materials characterised by their coercivity of hard-magnetic materials metals or alloys in the form of particles, e.g. powder
The present invention provides a method for preparing iron oxide magnetic particles and iron oxide magnetic particles prepared thereby, wherein the method includes (a) synthesizing a complex by reacting iron and one or more compounds selected from the group consisting of an aliphatic hydrocarbonate having 4 to 25 carbon atoms and an amine compound, (b) synthesizing an iron oxide crystal nucleus by mixing the complex with a mixture of an unsaturated aliphatic hydrocarbon-based compound having 4 to 25 carbon atoms and an ether-based compound, and (c) forming a shell by mixing the iron oxide crystal nucleus and an MXn compound with a mixture of an unsaturated aliphatic hydrocarbon-based compound having 4 to 25 carbon atoms and an ether-based compound, wherein M is a heavy atom element, X is a halogen element, and n is an integer of 1 to 6.
H01F 1/00 - Magnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties
H01F 1/34 - Magnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties of inorganic materials characterised by their coercivity of soft-magnetic materials non-metallic substances, e.g. ferrites
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
B82Y 25/00 - Nanomagnetism, e.g. magnetoimpedance, anisotropic magnetoresistance, giant magnetoresistance or tunneling magnetoresistance
B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
B82Y 40/00 - Manufacture or treatment of nanostructures
patents
